Insmed Incorporated reported $1.14B of revenue over the trailing twelve months, +186% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.14B (to Q2 2026). Net income: −$875M, trailing twelve months to Q2 2026. Free cash flow: −$808M, trailing twelve months to Q2 2026. Operating margin: −107%, trailing twelve months to Q2 2026.

INSMInsmed Incorporated

Healthcare

$100.66-30% 1Y

$100.66

$91.8852 weeks$211.41

INSM as reported

Insmed Incorporated reported $1.14B of revenue over the trailing twelve months, +186% on the year before. 10 reported series are charted on this page, each one as filed.

$1.14B

Revenue, trailing twelve months · to Q2 2026 · +186% against the twelve months before

Net income: −$875M
Net income · −15% year on year · trailing twelve months to Q2 2026
Free cash flow: −$808M
Free cash flow · −7.0% year on year · trailing twelve months to Q2 2026
Operating margin: −107%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for INSM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.14B	+186%	Q2 2026
Net income	−$875M	−15%	Q2 2026
EPS	−$4.10	−28%	Q2 2026
Gross margin	83%	n/a	Q2 2026
Operating margin	−107%	n/a	Q2 2026
Net margin	−110%	n/a	Q2 2026
ROE	−145%	n/a	Q2 2026
ROA	−51%	n/a	Q2 2026
ROIC	−802%	n/a	Q2 2026
Free cash flow	−$808M	−7.0%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.